Table 1 Clinical and pathological characteristics of MIBC patient cohorts in this study
Covariates | Training cohort (n = 200) | Testing cohort (n = 199) | TCGA cohort (n = 399) | P-value |
|---|---|---|---|---|
Age, no (%) | Â | Â | Â | Â |
 Young (≤ 65) | 74 (37%) | 85 (42.71%) | 159 (39.85%) | 0.2876 |
 Old (> 65) | 126 (63%) | 114 (57.29%) | 240 (60.15%) |  |
Gender, no (%) | Â | Â | Â | Â |
 Female | 57 (28.5%) | 48 (24.12%) | 105 (26.32%) | 0.3791 |
 Male | 143 (71.5%) | 151 (72.88%) | 294 (73.68%) |  |
Grade, no (%) | Â | Â | Â | Â |
 High Grade | 189 (94.5%) | 187 (93.97%) | 376 (94.24%) | 0.8185 |
 Low Grade | 9 (4.5%) | 11 (5.53%) | 20 (5.01%) |  |
 Unknown | 2 (1%) | 1 (0.5%) | 3 (0.75%) |  |
Stage, no (%) | Â | Â | Â | Â |
 Stage II | 64 (32%) | 62 (31.16%) | 126 (31.58%) | 0.9413 |
 Stage III–IV | 135 (67.5%) | 136 (68.34%) | 271 (67.92%) |  |
 Unknown | 1 (0.5%) | 1 (0.5%) | 2 (0.5%) |  |
T, no (%) | Â | Â | Â | Â |
 T2 | 62 (31%) | 55 (27.64%) | 117 (29.32%) | 0.5967 |
 T3–4 | 123 (61.5%) | 126 (63.32%) | 249 (62.41%) |  |
 Unknown | 15 (7.5%) | 18 (9.05%) | 33 (8.27%) |  |
M, no (%) | Â | Â | Â | Â |
 M0 | 89 (44.5%) | 103 (51.76%) | 192 (48.12%) | 0.8268 |
 M1 | 6 (3%) | 5 (2.51%) | 11 (2.76%) |  |
 Unknown | 105 (52.5%) | 91 (45.73%) | 196 (49.12%) |  |
N, no (%) | Â | Â | Â | Â |
 N0 | 120 (60%) | 113 (56.78%) | 233 (58.4%) | 0.872 |
 N1–3 | 63 (31.5%) | 63 (31.66%) | 126 (31.58%) |  |
 Unknown | 17 (8.5%) | 23 (11.56%) | 40 (10.03%) |  |
Fustat, no (%) | Â | Â | Â | Â |
 Alive | 114 (57%) | 109 (54.77%) | 223 (55.89%) | 0.7286 |
 Dead | 86 (43%) | 90 (45.23%) | 176 (44.11%) |  |